Galsulfase (Naglazyme)
The objective of this review is to evaluate the beneficial and harmful effects of galsulfase 1 mg/kg IV infusion once weekly as long-term enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) (MPS VI)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 2016 Nov
|
| Series: | Common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to evaluate the beneficial and harmful effects of galsulfase 1 mg/kg IV infusion once weekly as long-term enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) (MPS VI) |
|---|---|
| Physical Description: | 1 online resource illustration |